CAIRO5: FOLFOXIRI + Bevacizumab vs FOLFOX/FOLFIRI + Bevacizumab in Patients With Initially Unresectable Colorectal Liver Metastases and Right-Sided and/or RAS/BRAFV600E-Mutated Primary Tumors

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Among patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAFV600E-mutated primary tumors, FOLFOXIRI + bevacizumab was associated with superior outcomes vs FOLFOX or FOLFIRI + bevacizumab with an increase in manageable toxicity.
Format: Microsoft PowerPoint (.ppt)
File Size: 141 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings